 The FDA has granted Breakthrough Device Designation to Nyxoah SA NASDAQ: NYXH Genio bilateral hypoglossal nerve stimulation system. The system treats adult patients with moderate to severe Obstructive Sleep Apnea OSA and Complete Concentric Collapse CCC of the soft palate. 